US exports may drive top Indian pharma companies to grow 20% in 2013
is mainly driven by the sheer size of generic opportunities in the US market. The US generic market size is about USD 100 billion and may grow at a CAGR of 8-9 per cent in the medium term on account of patent expiries coupled with
pro-generic healthcare policies," the agency said.
During 2013-2015, opportunities on account of patent expiries will amount to around USD 125 billion. Indian players with robust product portfolio, filings and necessary
manufacturing infrastructure are well placed to capitalise on this upcoming opportunity.
The R&D spends of Indian pharma companies have been increasing year-on-year.
"On the back of large investments, the companies have built a strong pipeline of products to be sold in the US. During 2011, Indian pharma companies' filings were 51 per cent of the total ANDA (abbreviated new drug applications) filings compared with 49 per cent in 2010 and 45% in 2009.
"Also, Indian companies' share of ANDA approvals increased in 2012 at 37 per cent (33 per cent in FY11). Total ANDAs of Indian companies approved by USFDA in 2012 was 178 (out of a total of 476) versus 144 (431)in 2011, according to India
Ratings.
Be the first to comment.
